LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
9.67
+0.32 (3.42%)
Apr 2, 2026, 4:00 PM EDT - Market closed
LENZ Therapeutics Revenue
In the year 2025, LENZ Therapeutics had annual revenue of $19.09M. LENZ Therapeutics had revenue of $1.59M in the quarter ending December 31, 2025.
Revenue (ttm)
$19.09M
Revenue Growth
n/a
P/S Ratio
15.88
Revenue / Employee
$125,579
Employees
152
Market Cap
303.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.09M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 15.00M | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Foghorn Therapeutics | 30.91M |
| Opus Genetics | 14.20M |
| Prelude Therapeutics | 12.14M |
| Ovid Therapeutics | 7.25M |
| Surrozen | 3.48M |
| Neurogene | 925.00K |
| Inhibikase Therapeutics | 1.00 |
| Adlai Nortye | -1.35M |
LENZ News
- 4 days ago - LENZ Therapeutics: Speculative But Strong Buy - Seeking Alpha
- 11 days ago - LENZ Therapeutics, Inc. (LENZ) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 19 days ago - LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026 - GlobeNewsWire
- 26 days ago - LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia - GlobeNewsWire
- 5 weeks ago - LENZ Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Calamos Timpani Small Cap Growth Fund Q4 2025 Contributors And Detractors - Seeking Alpha
- 2 months ago - New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug - Benzinga